Results 1 to 10 of about 157,426 (292)
Immune checkpoint inhibitors [PDF]
Journal of Experimental Medicine, 2021 Three papers by James Allison and Tasuku Honjo published in JEM between 1995 and 2000 crystallized seminal insights into the role of CTLA-4 and PD-1 in immunosuppression (Krummel and Allison. 1995. J. Exp. Med.https://doi.org/10.1084/jem.182.2.459; van Elsas et al. 1999. J. Exp. Med.https://doi.org/10.1084/jem.190.3.355; Freeman et al. 2000. J.
Kroemer, Guido, Zitvogel, Laurence
+8 more sources
Immune checkpoint inhibitors [PDF]
Journal of Cell Biology, 2019 Hui details the cell biology underlying the action of immune checkpoint inhibitors.
Pawel Kalinski, Per Basse
+11 more sources
Immune checkpoint inhibitor-induced inflammatory arthritis [PDF]
Clinical MedicineImmune checkpoint inhibitors (ICI) used for the treatment of malignancy are associated with immune-related adverse events, which include inflammatory arthritis.
Benjamin A. Fisher +5 more
doaj +2 more sources
Role of mitochondrial metabolism in immune checkpoint inhibitors-related myocarditis
Frontiers in Cardiovascular Medicine, 2023 BackgroundImmune checkpoint inhibitor-related myocarditis is the deadliest complication of immunotherapy. However, the underlying pathophysiological mechanisms of its occurrence and development remain unclear. Due to the long-term lack of effective early
Xin Zhang +8 more
doaj +1 more source
The role of kidney biopsy in immune checkpoint inhibitor nephrotoxicity
Frontiers in Medicine, 2022 Immune checkpoint inhibitors, medications that boost host immune response to tumor cells, are now at the forefront of anti-cancer therapy. While efficacious in the treatment of patients with advanced cancer, immune checkpoint inhibitors can lead to ...
Emily M. Moss +2 more
doaj +1 more source
Immune Checkpoint Inhibitors and Kidney Toxicity: Advances in Diagnosis and Management
Kidney Medicine, 2021 Immune checkpoint inhibitors are now approved for more than 50 indications, and increasing numbers of patients with advanced cancer are receiving immunotherapy.
Harish Seethapathy +2 more
doaj +1 more source
Respiratory Medicine Case Reports, 2021 Background: Immune checkpoint inhibitor therapy is rapidly becoming front line adjuvant or primary therapy in a number of solid cancer types. Since many of these cancers are a result of tobacco smoking, a large number of these patients will have ...
Viswam S. Nair +2 more
doaj +1 more source
Immune Checkpoint Inhibitors [PDF]
JAMA Oncology, 2015 Undoubtedly the discovery of immune checkpoints such as CTLA-4 and PD-1 has been crucial to the development of cancer immunotherapy. Although these molecules were originally discovered as molecules playing a role in T cell activation or apoptosis, subsequent preclinical research showed their important role in the maintenance of peripheral immune ...
John B A G, Haanen, Caroline, Robert
openaire +3 more sources
Gut microbiota shed new light on the management of immune‐related adverse events
Thoracic Cancer, 2022 Immunotherapy has dramatically revolutionized the therapeutic landscape for patients with cancer. Although immune checkpoint inhibitors are now accepted as effective anticancer therapies, they introduce a novel class of toxicity, termed immune‐related ...
Bei Tan +8 more
doaj +1 more source
Esophagitis dissecans superficialis with immune checkpoint inhibitor therapy
Current Problems in Cancer: Case Reports, 2021 Immune checkpoint inhibitors represent an important advance in cancer treatment, but immune mediated adverse events associated with their use can be severe and life-threatening.
Alexis Coolidge +3 more
doaj +1 more source